[{"orgOrder":0,"company":"Navigo Proteins","sponsor":"SCK CEN","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Navigo Proteins","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navigo Proteins \/ SCK CEN","highestDevelopmentStatusID":"4","companyTruncated":"Navigo Proteins \/ SCK CEN"}]

Find Clinical Drug Pipeline Developments & Deals by Navigo Proteins

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The two organizations aim to accelerate the development of radioligand therapies – highly specific, targeted therapies offering high efficacy with minimal side effects for cancer patients.

                          Product Name : Undislcosed

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          April 03, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : SCK CEN

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank